[{"id":"6a7e9990-a739-46e3-a955-92f98bf580c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04927416","created_at":"2021-06-16T18:52:38.190Z","updated_at":"2025-02-25T15:35:06.877Z","phase":"Phase 2","brief_title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","source_id_and_acronym":"NCT04927416","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 overexpression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 11/30/2030","primary_completion_date":" 11/30/2030","study_txt":" Completion: 11/30/2030","study_completion_date":" 11/30/2030","last_update_posted":"2025-02-10"},{"id":"1c396f9f-301a-4705-afde-65c99cd26512","acronym":"LIBRETTO-321","url":"https://clinicaltrials.gov/study/NCT04280081","created_at":"2021-01-18T20:46:57.085Z","updated_at":"2025-02-25T16:32:06.121Z","phase":"Phase 2","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","source_id_and_acronym":"NCT04280081 - LIBRETTO-321","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-07"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"0a783bcc-4ad7-4844-9ff8-1c57f587c024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759911","created_at":"2021-02-18T22:55:11.009Z","updated_at":"2025-02-25T16:53:32.021Z","phase":"Phase 2","brief_title":"Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer","source_id_and_acronym":"NCT04759911","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2021","start_date":" 02/26/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-04"},{"id":"fc12ec5e-bd90-482d-9d25-a68cd6f10bca","acronym":"LIBRETTO-531","url":"https://clinicaltrials.gov/study/NCT04211337","created_at":"2021-01-18T20:30:33.890Z","updated_at":"2025-02-25T16:52:48.085Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","source_id_and_acronym":"NCT04211337 - LIBRETTO-531","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"ad64e5d0-95d3-4f41-a430-f89469610dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914300","created_at":"2023-12-06T21:16:15.541Z","updated_at":"2024-07-02T16:34:26.125Z","phase":"Phase 2","brief_title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03914300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"f51f49cf-f0c9-4ddc-b426-bcb5de14fa69","acronym":"","url":"https://clinicaltrials.gov/study/NCT04888481","created_at":"2021-05-17T18:56:01.878Z","updated_at":"2024-07-02T16:35:08.494Z","phase":"Phase 2","brief_title":"68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors","source_id_and_acronym":"NCT04888481","lead_sponsor":"University of Alberta","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-22"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"a9ff4f76-2282-4d1f-9d45-07b786992ee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241834","created_at":"2022-02-16T18:53:36.129Z","updated_at":"2024-07-02T16:35:12.547Z","phase":"Phase 1","brief_title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","source_id_and_acronym":"NCT05241834","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-27"},{"id":"cbadcf07-a7e7-4ec4-b497-346814eb3bc4","acronym":"LIBRETTO-121","url":"https://clinicaltrials.gov/study/NCT03899792","created_at":"2021-01-18T19:12:12.872Z","updated_at":"2024-07-02T16:35:15.915Z","phase":"Phase 1/2","brief_title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","source_id_and_acronym":"NCT03899792 - LIBRETTO-121","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-03-07"},{"id":"84dc749a-0183-451c-8fd6-1c9e5b7e76b1","acronym":"LIBRETTO-001","url":"https://clinicaltrials.gov/study/NCT03157128","created_at":"2021-01-17T17:11:02.877Z","updated_at":"2024-07-02T16:35:16.573Z","phase":"Phase 1/2","brief_title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)","source_id_and_acronym":"NCT03157128 - LIBRETTO-001","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 875","initiation":"Initiation: 05/02/2017","start_date":" 05/02/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-03-04"},{"id":"1cd4bf5f-edfe-4d2a-b079-73a5000d620a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225259","created_at":"2022-02-05T18:29:52.250Z","updated_at":"2024-07-02T16:35:17.299Z","phase":"","brief_title":"Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","source_id_and_acronym":"NCT05225259","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-28"},{"id":"cd334664-b55d-49f3-960b-50fed3f6d9ca","acronym":" AcSé Pembrolizumab study","url":"https://clinicaltrials.gov/study/NCT03012620","created_at":"2021-01-18T14:49:27.880Z","updated_at":"2025-02-25T16:05:41.112Z","phase":"Phase 2","brief_title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012620 -  AcSé Pembrolizumab study","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":" | ","alterations":" PD-L1 underexpression • FASN-L","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • FASN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 12/14/2023","study_completion_date":" 12/14/2023","last_update_posted":"2024-02-28"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"32e67e72-a7dc-4ce5-9a04-0d11b361ae23","acronym":"","url":"https://clinicaltrials.gov/study/NCT05675605","created_at":"2023-01-09T15:59:22.674Z","updated_at":"2024-07-02T16:35:21.856Z","phase":"Phase 1/2","brief_title":"A Study of TY-1091 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05675605","lead_sponsor":"TYK Medicines, Inc","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-1091"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-30"},{"id":"37ae51b7-8ad9-4388-90cd-0f703c6c8ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03145857","created_at":"2021-01-18T15:30:16.237Z","updated_at":"2024-07-02T16:35:21.781Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use","source_id_and_acronym":"NCT03145857","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-01-30"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"557b19f9-7188-4df8-9db3-bfc502e77692","acronym":"AcceleRET-MTC","url":"https://clinicaltrials.gov/study/NCT04760288","created_at":"2021-02-18T22:55:15.019Z","updated_at":"2024-07-02T16:35:24.361Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","source_id_and_acronym":"NCT04760288 - AcceleRET-MTC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET • CEACAM5","pipe":" | ","alterations":" RET mutation","tags":["RET • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Gavreto (pralsetinib) • Caprelsa (vandetanib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 04/12/2035","study_completion_date":" 04/12/2035","last_update_posted":"2024-01-05"},{"id":"93b46964-c26a-4b82-8478-1f30666c235e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01709435","created_at":"2021-01-18T07:26:51.317Z","updated_at":"2024-07-02T16:35:25.380Z","phase":"Phase 1","brief_title":"Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT01709435","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 11/14/2012","start_date":" 11/14/2012","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2023-12-22"},{"id":"2ce71cc8-c99e-442e-ada8-43ed288e9bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06121271","created_at":"2023-11-07T16:14:39.298Z","updated_at":"2024-07-02T16:35:26.861Z","phase":"Phase 2","brief_title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","source_id_and_acronym":"NCT06121271","lead_sponsor":"University College, London","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 11/06/2027","primary_completion_date":" 11/06/2027","study_txt":" Completion: 11/06/2027","study_completion_date":" 11/06/2027","last_update_posted":"2023-12-07"},{"id":"ae4bc21b-56da-43de-9d91-fda963c4eb35","acronym":"","url":"https://clinicaltrials.gov/study/NCT05541380","created_at":"2022-09-15T16:06:07.463Z","updated_at":"2024-07-02T16:35:28.349Z","phase":"","brief_title":"A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)","source_id_and_acronym":"NCT05541380","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-11-22"},{"id":"a54c5bf1-77a7-4e44-bb57-e245104dfd72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780517","created_at":"2021-01-18T18:41:54.388Z","updated_at":"2024-07-02T16:35:31.196Z","phase":"Phase 1","brief_title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","source_id_and_acronym":"NCT03780517","lead_sponsor":"Boston Pharmaceuticals","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeteletinib (BOS-172738)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2023-10-30"}]